Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha (evolocumab) ...
More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t generate much sales momentum behind the product. Its latest gambit is to make ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback